


Journal Pre-proof

Mild versus severe COVID-19: laboratory markers

Thirumalaisamy P. Velavan Christian G. Meyer



PII: S1201-9712(20)30277-0

DOI: <https://doi.org/doi:10.1016/j.ijid.2020.04.061>

Reference: IJID 4149

To appear in: *International Journal of Infectious Diseases*

Received Date: 5 April 2020

Revised Date: 15 April 2020

Accepted Date: 22 April 2020

Please cite this article as: Velavan TP, Meyer CG, Mild versus severe COVID-19: laboratory markers, *International Journal of Infectious Diseases* (2020), doi: <https://doi.org/10.1016/j.ijid.2020.04.061>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

Mild versus severe COVID-19: laboratory markers

Thirumalaisamy P. Velavan^{1,2,3,4*#}, Christian G. Meyer^{1,2,3*}

¹ Institute of Tropical Medicine, Universitätsklinikum Tübingen, Germany.

² Vietnamese German Center for Medical Research, Hanoi, Vietnam.

³ Faculty of Medicine, Duy Tan University, Da Nang, Vietnam.

⁴ Fondation Congolaise pour la Recherche Médicale, Brazzaville, Congo

Correspondence:

Prof. Dr. T.P. Velavan, Institute of Tropical Medicine, Universitätsklinikum Tübingen, Germany. Tel.: +49-7071-2985981; Email: velavan@medizin.uni-tuebingen.de

*Both authors contributed equally

Key words: Laboratory markers; COVID-19, Mild and severe COVID-19; Biomarkers

Words:1480 (Including tables)

Abstract:

The number of COVID-19 patients is increasing dramatically worldwide and treatment in intensive care units (ICU) has become a major challenge, the early recognition of severe forms of is absolutely essential for timely triaging of patients. While the clinical status, in particular Peripheral oxygen saturation (SpO₂) levels and concurrent comorbidities of COVID-19 patients largely determines the need of their admittance to ICUs, several laboratory parameters may facilitate the assessment of disease severity. In hospitalized patients, clinicians should consider low lymphocyte count as well as the serum levels of CRP, D-dimers, ferritin and IL-6 which may be used in risk stratification to predict severe and fatal COVID-19. The more several or all of these parameters are altered, the more likely it is that the course of the disease will be unfavourable.

Highlights

- several laboratory parameters may facilitate the assessment of COVID-19 severity
- discriminating mild from severe COVID-19 disease.
- Cumulative data from clinical characteristics of COVID-19 patients
- low lymphocyte count as well as the serum levels of CRP, D-dimers, ferritin and IL-6.

As the number of COVID-19 patients is increasing dramatically worldwide and treatment in intensive care units (ICU) has become a major challenge, the early recognition of severe forms of COVID-19 is absolutely essential for timely triaging of patients. SARS-CoV-2 infection, especially in older patients and those with pre-existing illness, progress to severe disease with critical respiratory symptoms and significant pulmonary changes visible by imaging techniques. The changes include ground glass opacities, patchy consolidation, alveolar exudates and interlobular involvement, ultimately prognosticating deterioration [1]. Further to recognized risk factors such as old age and underlying comorbidities, in particular cardiovascular diseases, diabetes, respiratory diseases and other conditions [2], several markers have been identified that modulate the course of COVID-19. Here we summarize laboratory markers that might be useful in indicating progression from mild to severe disease (Table 1).

COVID-19 patients admitted to ICUs had higher concentrations of proinflammatory cytokines and, importantly, increased secretion of those T-helper-2 (Th2) cytokines suppressing inflammation [1]. Given the high levels of cytokines induced by SARS-CoV-2, treatment to reduce inflammation-related lung damage is critical. Any intervention to reduce inflammation will, however, affect negatively the viral clearance. Among the various inflammatory cytokine and chemokine levels assessed in several studies, tumour necrosis factor alpha (TNF- α), interferon- γ -induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), chemokine (C-C motif) ligand 3 (CCL-3) and distinct interleukins (IL) (IL-2, IL-6, IL-7, IL-10) were significantly associated with disease severity and particularly observed among cases admitted to ICUs. IL-1 and IL-8 were not associated with severity (Table1). Apparently, the

serum levels of some interleukins bear the potential to discriminate between mild and severe disease and possibly may be used as prognostic markers.

Among haematological parameters, lymphopenia is clearly associated with disease severity; patients who died from COVID-19 had significantly lower lymphocyte counts than survivors. In fact, repletion of lymphocytes may be an important factor for recovery [3]. Other blood cells, including white blood cells, neutrophils, eosinophils, platelets and CD8 cell counts were partly only predictors in discriminating mild from severe COVID-19 (Table1); their significance is still ambiguous. Granulocyte colony stimulating factor (G-CSF) was elevated in ICU patients and significantly associated with the severity of disease (Table1).

Patients with severe COVID-19 appear to have signs of liver dysfunction more frequently than those with milder disease. An increase in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin levels has been observed among many ICU patients [4] (Table 1). Infection of liver cells with SARS-CoV-2 cannot be excluded, as 2-10% of patients with COVID-19 have diarrhoea and viral RNA has been detected in both stool and blood samples, which implies the possibility of hepatic virus presence [5]. It is also likely that any immune-mediated inflammation, in particular cytokine storm, but also pneumonia-associated hypoxia, may lead to liver damage in critically ill COVID-19 patients [4]. C-reactive protein (CRP) levels are increased in COVID-19 patients and it has been shown that survivors had median CRP values of approximately 40 mg/L, while non-survivors had median values of 125 mg/L, indicating a strong correlation with disease severity and prognosis [6] (Table 1). Other predictors of poor outcome include the serum levels of ferritin and lactate dehydrogenase (LDH). Elevated ferritin levels due to secondary hemophagocytic lymphohistiocytosis (SHLH) and cytokine storm syndrome have been reported in severe COVID-19 patients. Based on body temperature, organomegaly, blood cell cytopenia, triglycerides, fibrinogen as well as AST and ferritin levels, a predictive H-score was proposed to estimate the risk of developing secondary hemophagocytic lymphohistiocytosis [7].

Correlations of abnormal coagulation parameters with poor prognosis were observed (Table 1). Non-survivors showed significantly higher levels of plasma D-dimers and fibrin degradation products, increased prothrombin times and activated partial thromboplastin times compared to survivors [8]. Coagulopathy and overt disseminated intravascular coagulation appear to be associated with high mortality rates. Among the coagulation parameters, D-dimer elevation >1 ug/L was the strongest independent predictor of mortality [2]. Elevated cardiac troponin I levels indicating heart injury are also predictive of mortality in critically ill patients [9;10].

The haematological and coagulation parameters summarized here as well as increased inflammatory reactions caused by various cytokines and liver enzymes are a globally observed phenomenon in COVID-19 patients. While the clinical status, in particular SpO₂ levels and concurrent comorbidities of COVID-19 patients largely determines the need of their admittance to ICUs, several laboratory parameters may facilitate the assessment of disease severity and rational triaging. The more several or all of these parameters are altered, the more likely it is that the course of the disease will be unfavourable. In hospitalized patients, clinicians should consider low lymphocyte count as well as the serum levels of CRP, D-dimers, ferritin and IL-6 which may be used in risk stratification to predict severe and fatal COVID-19. In order to further support clinical decision making, large datasets and sound metanalyses are now urgently required.

Acknowledgements

All authors have an academic interest and contributed equally. TPV is a member of the Pan African Network for Rapid Research, Response, and Preparedness for Infectious Diseases Epidemics consortium (PANDORA-ID-NET).

Conflict of interest: All authors disclose no conflict of interest.

141

142 **Funding Source:** European and Developing Countries Clinical Trials Partnership (EDCTP)

143 Pan African Network for Rapid Research, Response, and Preparedness for Infectious

144 Diseases Epidemics consortium (PANDORA-ID-NET- EDCTP grant ID: RIA2016E-1609).

Journal Pre-proof

Table 1: Haematological, Cytokines, Liver enzymes and Coagulation parameters in mild vs. severe COVID19 patients

Haematological parameters	COVID-19 cases/cases (n)	Interpretation	Reference
White blood cell count (WBC)	15 mild, 9 severe, 5 critical cases	normal or ↓ in 23/29	[11]
	41 cases (13 ICU cases)	↑ in ICU cases	[1]
	43 (28 mild, 15 severe)	normal in all cases	[13]
	1994 cases (meta-analysis)	↓ in 29% of cases	[15]
	54 cases	normal in cases	[16]
Neutrophil count	41 cases (13 ICU cases)	↑ in ICU cases	[1]
	201 cases	↑ in ARDS cases	[17]
	12 cases	↓ in most cases	[18]
Lymphocyte count	Familial cluster, 6 cases	↓ in 2 of 3 cases >60 years	[19]
	15 mild, 9 severe, 5 critical cases	↓ in 20/29	[11]
	41 cases (13 ICU cases)	↓ in ICU cases	[1]
	140 cases	↓ in most cases	[20]
	43; 28 mild, 15 severe cases	normal in cases	[13]
	1994 cases (meta-analysis)	↓ in most cases	[15]
	54 cases	↓ in most cases	[16]
	12 cases	↓ in most cases	[18]
	30 cases	↓ in 40% cases	[21]
Eosinophil count	140 cases	↓ in most cases	[20]
Thrombocyte count	Familial cluster, 6 cases	↓ in 2 of 3 cases >60 yrs.	[19]
	70 mild, 85 severe cases	normal; slightly lower in severe cases	[14]
Granulocyte-colony stimulating factor (G-CSF)	41 cases (13 ICU cases)	↑ in ICU cases	[1]
CD8 cell count	12 cases	↓ in most cases	[18]
Cytokines	COVID-19 cases (n)	Interpretation	Reference

Tumour necrosis factor alpha (TNF-alpha)	41 cases (13 ICU cases)	↑ in ICU cases	[1]
Interferon-γ induced protein 10 (IP-10),	41 cases (13 ICU cases)	↑ in ICU cases	[1]
Monocyte chemoattractant protein 1 (MCP-1)	41 cases (13 ICU cases)	↑ in ICU cases	[1]
Chemokine (C-C Motif) Ligand 3 (CCL-3)	41 cases (13 ICU cases)	↑ in ICU cases	[1]
Interleukin-1 (IL-1)	15 mild, 9 severe, 5 critical cases	normal in all cases	[11]
Interleukin-2 (IL-2)	41 cases (13 ICU cases)	↑ in ICU cases	[1]
Interleukin-2 receptor (IL-2R)	15 mild, 9 severe, 5 critical cases	↑, >critical >severe >mild	[11]
Interleukin-6 (IL-6)	15 mild, 9 severe, 5 critical cases	↑ according to severity >critical >severe >mild	[11]
	69 cases, mortality 7,5%	↑ in the patient group with SpO ₂ <90%	[12]
	150 cases	↑ in non-survivors	[7]
	43; 28 mild, 15 severe cases	↑ in severe cases	[13]
	70 mild, 85 severe cases	↑; higher in severe cases	[14]
Interleukin-7 (IL-7)	41 cases (13 ICU cases)	↑ in ICU cases	[1]
Interleukin-8 (IL-8)	15 mild, 9 severe, 5 critical cases	normal in all cases	[11]
Interleukin-10 (IL-10)	15 mild, 9 severe, 5 critical cases	normal in all cases	[11]
	69 cases, mortality 7,5%	↑ in the patient group with SpO ₂ <90%	[12]
	41 cases (13 ICU cases)	↑ in ICU cases	[1]

149

Liver enyzmes/biomarkers	COVID-19 cases/cases (n)	Interpretation	Reference
Albumin	15 mild, 9 severe, 5 critical cases	↓ in 15/29	[11]
	41 cases (13 ICU cases)	↓ in ICU cases	[1]
	12 cases	↓ in most cases	[18]
	70 mild, 85 severe cases	↓ in all cases	[14]
Alanine aminotransferase (ALT)	15 mild, 9 severe, 5 critical cases	-	[11]
	41 cases (13 ICU cases)	↑ in ICU cases	[1]
Aspartate aminotransferase (AST)	15 mild, 9 severe, 5 critical cases	-	[11]
Total bilirubin	41 cases (13 ICU cases)	↑ in ICU cases	[1]
	15 mild, 9 severe, 5 critical cases	- normal in all cases	[11]
Glucose	43; 28 mild, 15 severe cases	↑ in severe cases	[13]
Serum creatinine	126 mild, 24 severe cases	↑ in severe cases	[11]

Lactate dehydrogenase (LDH)	Familial cluster, 6 cases	↑ in the 3 cases >60 yrs.	[19]
	15 mild, 9 severe, 5 critical cases	↑ in 20/29	[11]
	69 cases, mortality 7,5%	↑ in the patient group with SpO ₂ <90%	[12]
	41 cases (13 ICU cases)	↑ in ICU cases	[1]
	201 cases	↑ in ARDS cases	[17]
	1994 cases (meta-analysis)	↑ in 28% of cases	[15]
	54 cases	↑ in most cases	[16]
	12 cases	↑ in all cases	[18]
	70 mild, 85 severe cases	↑ in severe cases	[14]
C-reactive protein (CRP)	Familial cluster, 6 cases	↑ in the 3 cases >60 yrs.	[19]
	126 mild, 24 severe cases	higher in severe cases	[22]
	15 mild, 9 severe, 5 critical cases	↑ in 27/29	[11]
	69 cases, mortality 7,5%	↑ in cases with SpO ₂ <90%	[12]
	140 cases	↑ in severe cases	[20]
	43; 28 mild, 15 severe cases	↑ in severe cases	[13]
	1994 cases (meta-analysis)	↑ in 44% of cases	[15]
	54 cases	↑ in most cases	[16]
	12 cases	↑ in most cases	[18]
Procalcitonin (PCT)	70 mild, 85 severe cases	↑ in all cases, higher in severe cases	[14]
	140 cases	↑ in severe cases	[20]
Ferritin	70 mild, 85 severe cases	↑ in all cases	[14]
	150	↑ in non-survivors	[7]
NT-proBNP	126 mild, 24 severe cases	↑ in severe cases	[22]
Cardiac troponin I	126 mild, 24 severe cases	↑ in severe cases	[22]
Cardiac troponin I (meta-analysis)	218 mild, 123 severe cases	↑ in severe cases	[9]
	138 hospitalized severe cases	↑ in severe cases	[10]
Angiotensin II level	12 cases	↑ in cases	[18]

Coagulation parameters	COVID-19 cases/cases (n)	Interpretation	Reference
d-dimers	191 cases, 91 with comorbidities	↑ in non-survivors	[2]

150

	94 cases	↑ in cases vs. controls	[23]
	201 cases	↑ in ARDS cases	[17]
	140 cases	↑ in severe cases	[20]
	43; 28 mild, 15 severe cases	↑ in severe cases	[13]
	30 cases	↑ in 17% of cases	[21]
	70 mild, 85 severe cases	normal; slightly higher in severe cases	[14]
	183 cases; 21 non-survivors	↑ in all cases, higher in non-survivors	[8]
Antithrombin (AT)	94 cases	↓ in cases vs. controls	[23]
Prothrombin time (PT)	94 cases	↓ in cases vs. controls	[23]
	41 cases (13 ICU cases)	↑ in ICU cases	[1]
	183 cases; 21 non-survivors	↑ in non-survivors	[8]
Activated partial thromboplastin time (APTT)	183 cases; 21 non-survivors	↑ in non-survivors	[8]
Thrombin clotting time (TCT)	94 cases	shorter in critical cases vs. controls	[23]
	43; 28 mild, 15 severe cases	↑ in severe cases	[13]
Fibrin degradation products (FDP)	94 cases	↑ in cases vs. controls	[23]
	183 cases; 21 non-survivors	↑ in non-survivors	[8]
Fibrinogen	94 cases	↑ in cases vs. controls	[23]
	43; 28 mild, 15 severe cases	↑ in severe cases	[13]
	183 cases; 21 non-survivors	↑ in all cases, higher in non-survivors	[8]

ARDS: acute respiratory distress syndrome; **ICU:** Intensive care unit; **ARDS:** acute respiratory distress syndrome; **CD8:** cluster of differentiation 8
SpO₂: Peripheral oxygen saturation; **NT-proBNP:** N-terminal pro b-type natriuretic peptide

Reference List

1. Huang C, Wang Y, Li X *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395:497-506.
2. Zhou F, Yu T, Du R *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020.
3. Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. *Lancet Respir.Med.* 2020.
4. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol.Hepatol.* 2020.
5. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? *Lancet Gastroenterol.Hepatol.* 2020; 5:335-7.
6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020.
7. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020.
8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J.Thromb.Haemost.* 2020.
9. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. *Prog.Cardiovasc.Dis.* 2020.
10. Wang D, Hu B, Hu C *et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.
11. Chen L, Liu HG, Liu W *et al.* [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. *Zhonghua Jie.He.He.Hu Xi.Za Zhi.* 2020; 43:203-8.
12. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. *Clin.Infect.Dis.* 2020.
13. Gao Y, Li T, Han M *et al.* Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. *J.Med.Virol.* 2020.
14. Mo P, Xing Y, Xiao Y *et al.* Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin.Infect.Dis.* 2020.
15. Li LQ, Huang T, Wang YQ *et al.* 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. *J.Med.Virol.* 2020.

16. Li YY, Wang WN, Lei Y *et al.* [Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia]. *Zhonghua Jie.He.He.Hu Xi.Za Zhi.* 2020; 43:E023.
17. Wu C, Chen X, Cai Y *et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern.Med.* 2020.
18. Liu Y, Yang Y, Zhang C *et al.* Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci.China Life Sci.* 2020; 63:364-74.
19. Chan JF, Yuan S, Kok KH *et al.* A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020; 395:514-23.
20. Zhang JJ, Dong X, Cao YY *et al.* Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020.
21. Liu M, He P, Liu HG *et al.* [Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia]. *Zhonghua Jie.He.He.Hu Xi.Za Zhi.* 2020; 43:E016.
22. Chen C, Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. *Zhonghua Xin.Xue.Guan.Bing.Za Zhi.* 2020; 48:E008.
23. Han H, Yang L, Liu R *et al.* Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin.Chem.Lab Med.* 2020.